Brighton Collaboration Releases New Template for Evaluating VSV-Based Lassa Fever Vaccines The Brighton Collaboration is proud to...

This manuscript uses the BRAVATO template to report the key considerations for a benefit-risk assessment of the coronavirus diseas...

This paper uses a BRAVATO protein template to review the features of Novavax’s recombinant adjuvanted spike protein vaccine to p...

Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral...

Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Asse...

Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and exp...

The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This pape...

The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other...

This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus...